Lawrence Eichenfield, MD

In this segment of his interview, Eichenfield highlights the safety and tolerability of roflumilast cream for children with atopic dermatitis in INTEGUMENT-OLE.

This segment of Eichenfield's interview highlights long-term safety findings on roflumilast cream .05% for children 2 - 5 years old with atopic dermatitis.

This interview highlights key points regarding new data on roflumilast cream 0.05% in children aged 2 to 5 years with atopic dermatitis.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

At the Maui Derm Hawaii 2026 conference, Lawrence Eichenfield, MD, spoke about highlights from his talk, ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’

This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’

In this interview, additional information on roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis was highlighted.

This interview follows the FDA’s recent approval of Arcutis's roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis.

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis.

Closing out its discussion on atopic dermatitis, the panel considers best practices and unmet needs in the treatment landscape.

A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.

Shared insight on the armamentarium of systemic agents available to treat atopic dermatitis.

A review of topical therapies that have been long utilized for patients with atopic dermatitis.

A brief review of patient and disease factors that inform selection of therapy for atopic dermatitis.

Expert insight on nonpharmacological strategies to treat atopic dermatitis and improve patient quality of life.

A brief evaluation of the concomitant use of JAK inhibitors, topical or systemic, in patients with atopic dermatitis.

Switching its focus to systemic JAK inhibitors, the panel reviews real-world use of available agents to treat patients with atopic dermatitis.

The panelists discuss real-world use of topical ruxolitinib in atopic dermatitis management given safety, efficacy, and availability.

Considerations for topical ruxolitinib with deference to positive clinical trial results in atopic dermatitis.

Shared insight on the available JAK inhibitors for atopic dermatitis, both topical and systemic.

Experts reflect on the various comorbid conditions associated with atopic dermatitis and how they can affect patients.

Comprehensive discussion on how atopic dermatitis can impact a patient’s quality of life.

Considerations for persistent atopic dermatitis vs outgrowing disease, followed by triggers that can result in flare-ups.

Shared insight on the ways a child or adult may present with atopic dermatitis.

A panel of experts review the pathophysiology of atopic dermatitis and its contributing factors.